Short answer
Kymera Therapeutics, Inc. (KYMR) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $65M (up 466.4% year over year) with net income of −$61M.
Q2 2026 key financials · XBRL
- Revenue
- $65M
- +466.4% YoY · +89.1% QoQ
- Net income
- −$61M
- +20.1% YoY · +11.6% QoQ
- Operating margin
- -116.3%
- EPS (diluted)
- −$0.62
- +34.7% YoY · +12.7% QoQ
Source: XBRL data from the Kymera Therapeutics, Inc. (KYMR) Q2 2026 10-Q on SEC EDGAR. USD.
Kymera Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $65.0M, up $53.5M YoY from $11.5M, driven by Gilead and Sanofi payments
- Operating loss $75.6M vs $84.6M YoY; operating margin -116.3% vs -736.6%
- Best-performing program STAT6 external costs $45.7M, up $23.5M YoY
- Cash, equivalents and marketable securities $1.505B; funding expected into 2029
- Near-term headwinds: substantially higher clinical development expenses and need for additional funding before product revenue
Risk Factors
- No newly triggered risk factor identified; section presents carried-forward risks from the 10-K
- Cash and marketable securities $1,505 million, expected to fund operations into 2029
- Accumulated deficit $1,196.4 million as of June 30, 2026
- STAT6 and IRF5 programs remain in early clinical development, limiting near-term product revenue
- No heterobifunctional degrader approved in the United States or Europe, heightening regulatory and technical uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kymera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.